FSTL1 and myocardial infarction: Epicardial delivery of recombinant FSTL1 protein or gene vectors has been shown to enhance cardiomyocyte survival and angiogenesis after MI, whereas loss-of-function models exacerbate myocardial injury (Wei et al., 2015).